Nantahala Capital Management Acquires 4.58% Stake in Fulcrum Therapeutics, Inc. (FULC)

Nantahala Capital Management, LLC, along with its principals Wilmot B. Harkey and Daniel Mack, filed an amended Schedule 13G on May 15, 2026, disclosing a beneficial ownership interest in Fulcrum Therapeutics, Inc. (FULC). As of the event date of March 31, 2026, the reporting persons collectively hold 3,050,040 shares of common stock, representing 4.58% of the company's outstanding shares. This filing marks an increase from a previously reported zero position, crossing the reporting threshold. The shares are held by funds and separately managed accounts under the control of Nantahala Capital Management. Each of the reporting persons shares voting and dispositive power over the reported shares. The filing was made under Rule 13d-1(b), indicating that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. Consequently, the reporting persons have certified that the holdings are passive in nature.